Sun Pharma Launches UNLOXCYT for Unresectable Skin Cancer Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 15 2026
0mins
Source: PRnewswire
- New Drug Launch: Sun Pharma announces the official launch of UNLOXCYT (cosibelimab-ipdl) in the U.S., providing a new treatment option for patients with unresectable or radiation-resistant metastatic cutaneous squamous cell carcinoma, marking a significant advancement in the company's oncology portfolio.
- Clinical Efficacy: Data from the CK-301-101 clinical trial shows a disease control rate of 71% for UNLOXCYT, with 13% of metastatic CSCC patients achieving complete response, highlighting its substantial efficacy in treatment.
- Patient Support Program: Sun Pharma introduces the UNLOXCYT SUPPORT patient access and affordability program, ensuring that patients can access the drug from day one of its launch, reflecting the company's strong commitment to patient needs.
- Safety Information: The safety profile of UNLOXCYT remains consistent with the original label, with common adverse reactions including fatigue and musculoskeletal pain, and no cases of Grade 3 or 4 pneumonitis reported, indicating good tolerability of the drug.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SUN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SUN
Wall Street analysts forecast SUN stock price to rise
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 62.820
Low
57.00
Averages
63.67
High
70.00
Current: 62.820
Low
57.00
Averages
63.67
High
70.00
About SUN
Sunoco LP is an energy infrastructure and fuel distribution master limited partnership operating across 32 countries and territories in North America, the Greater Caribbean, and Europe. Its midstream operations include a network of approximately 14,000 miles of pipeline and over 160 terminals. Its Fuel Distribution segment supplies motor fuel to independently operated dealer stations, distributors, commission agents and other consumers. Its Pipeline Systems segment includes an integrated pipeline and terminal network comprised of refined products, crude oil and ammonia pipelines and terminals. Through its Terminals segment, it operates four transmix processing facilities and 83 terminals. Its terminals provide storage and distribution services to support our fuel distribution business and other third-party customers. Its Refinery segment is composed of the Burnaby Refinery, which is responsible for the refining of fuel products and engaged in renewable business activities.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sun Pharmaceutical Acquires Innovcare Lifesciences for ₹2.71 Billion
- Acquisition Overview: Sun Pharmaceutical announced its acquisition of Innovcare Lifesciences for approximately ₹2.71 billion (about $28.73 million), aiming to expand its market share in the pharmaceutical industry.
- Transaction Value Analysis: The deal, valued at ₹2.71 billion, equivalent to about $28.73 million, reflects Sun Pharmaceutical's proactive approach in mergers and acquisitions, intending to enhance its product portfolio and competitive edge.
- Strategic Market Intent: By acquiring Innovcare, Sun Pharmaceutical can integrate its R&D resources and leverage Innovcare's technological advantages to boost product innovation, thereby meeting the evolving market demands.
- Future Growth Potential: This acquisition is expected to provide new growth opportunities for Sun Pharmaceutical, likely driving its long-term development in the pharmaceutical sector, particularly in the rapidly growing biopharmaceutical field.
See More
Kinder Morgan's Financial Stability and Continued Shareholder Returns
- Cash Flow Stability: Kinder Morgan's cash flows are anchored by 96% from take-or-pay, fee-based, or hedged contracts, with 65% from take-or-pay contracts, ensuring financial stability amid market fluctuations.
- Capital Allocation and Debt Management: In the first quarter, the company generated $1.49 billion in cash flow from operations, enabling support for dividends, capital expenditures, and growth investments while reducing its net debt-to-adjusted EBITDA ratio to 3.6x, enhancing financial flexibility.
- Commitment to Shareholder Returns: Kinder Morgan expects to return approximately $2.7 billion to shareholders by 2026, declaring a quarterly dividend of 29.75 cents per share in Q1, marking the ninth consecutive year of dividend increases, demonstrating a long-term commitment to shareholders.
- Market Performance and Valuation: Kinder Morgan's shares have risen 12.9% over the past year compared to an 18.8% increase in composite industry stocks, with an EV/EBITDA of 14.04x, below the industry average of 15.04x, indicating potential investment value.
See More
Quanta Services Appoints Joseph Kim to Board of Directors
- New Board Member: Quanta Services announced the appointment of Joseph Kim to its Board of Directors, whose extensive experience in supply chain and logistics is expected to bring new perspectives and enhance the board's strategic planning capabilities.
- Rich Leadership Experience: Kim currently serves as CEO of Sunoco GP LLC and has held executive roles at notable companies including Pizza Hut and Valero Energy, showcasing his deep background in the energy sector.
- Strategic Planning Expertise: Chairman Doyle N. Beneby noted that Kim's addition will enhance Quanta's capabilities in capital allocation and risk management, driving further growth in the energy infrastructure sector.
- Global Business Expansion: Quanta Services operates across the U.S., Canada, Australia, and other international markets, and Kim's leadership experience will aid the company in safely and efficiently completing various infrastructure projects worldwide.
See More
Sun Pharmaceutical Surpasses Quarterly Profit Estimates Driven by Specialty Drugs
- Quarterly Profit Surge: Sun Pharmaceutical reported a consolidated net profit of 27.14 billion rupees ($283 million) for the quarter ending March 31, marking a 26% increase from 21.50 billion rupees last year, exceeding analysts' expectations of 27.12 billion rupees, indicating strong performance in high-margin drug sectors.
- Specialty Drug Focus: The company's strategic emphasis on high-margin specialty medicines in dermatology, oncology, and obesity has led to this segment accounting for 22.2% of total sales, with revenue rising 20.1% to $354 million, showcasing its ability to counteract declining U.S. sales.
- Overall Revenue Growth: Sun Pharma's total revenue increased nearly 13% to 146.12 billion rupees, surpassing analysts' estimates of 145.26 billion rupees, reflecting the effectiveness of its diversified product portfolio and market strategies.
- Market Performance Insights: Despite a 1.1% decline in U.S. sales, the Indian market saw a robust growth of 14.8%, demonstrating strong domestic demand and positioning the company for enhanced competitiveness in the global market.
See More
Quanta Services Appoints New Board Member
- New Board Member: Quanta Services has appointed Joseph Kim to its Board of Directors, bringing extensive executive experience in supply chain and logistics, which will enhance the company's strategic planning and risk management capabilities.
- Leadership Background: Kim currently serves as CEO of Sunoco GP LLC and has held various executive roles at Pizza Hut and Valero Energy, showcasing his broad influence in the energy sector.
- Board Expectations: Doyle N. Beneby, the independent Chairman of Quanta Services, expressed anticipation for Kim to provide new perspectives to the board, enhancing the company's strategic decision-making and driving business growth.
- Industry Leadership: Quanta Services is a leader in utility and energy infrastructure solutions, and Kim's addition is expected to further solidify the company's market position and enhance its competitiveness in the global arena.
See More
Sunoco LP Shows Strong Technical Setup in Energy Sector
- Technical Breakthrough: Sunoco LP (SUN) stands out in the energy sector with a significant technical breakout above the 2014 peak, indicating a strong long-term bullish trend that is expected to benefit from volatility in crude oil prices.
- Strong Momentum: The monthly MACD shows robust momentum, suggesting that SUN's stock could continue to trend higher over the next few months, with a target price of approximately $78 that appears achievable.
- Relative Outperformance: Relative to the S&P 500 Index, SUN is projected to outperform by 2026, having formed a rounded bottom over the past year that reversed its cyclical downtrend, indicating a strong relative uptrend.
- Solid Support Levels: Former resistance has created strong support around $60, while the 50-day moving average can serve as a trailing stop near $66, ensuring stability for investors amid market fluctuations.
See More
Sun Pharmaceutical Acquires Innovcare Lifesciences for ₹2.71 Billion
- Acquisition Overview: Sun Pharmaceutical announced its acquisition of Innovcare Lifesciences for approximately ₹2.71 billion (about $28.73 million), aiming to expand its market share in the pharmaceutical industry.
- Transaction Value Analysis: The deal, valued at ₹2.71 billion, equivalent to about $28.73 million, reflects Sun Pharmaceutical's proactive approach in mergers and acquisitions, intending to enhance its product portfolio and competitive edge.
- Strategic Market Intent: By acquiring Innovcare, Sun Pharmaceutical can integrate its R&D resources and leverage Innovcare's technological advantages to boost product innovation, thereby meeting the evolving market demands.
- Future Growth Potential: This acquisition is expected to provide new growth opportunities for Sun Pharmaceutical, likely driving its long-term development in the pharmaceutical sector, particularly in the rapidly growing biopharmaceutical field.
See More
Kinder Morgan's Financial Stability and Continued Shareholder Returns
- Cash Flow Stability: Kinder Morgan's cash flows are anchored by 96% from take-or-pay, fee-based, or hedged contracts, with 65% from take-or-pay contracts, ensuring financial stability amid market fluctuations.
- Capital Allocation and Debt Management: In the first quarter, the company generated $1.49 billion in cash flow from operations, enabling support for dividends, capital expenditures, and growth investments while reducing its net debt-to-adjusted EBITDA ratio to 3.6x, enhancing financial flexibility.
- Commitment to Shareholder Returns: Kinder Morgan expects to return approximately $2.7 billion to shareholders by 2026, declaring a quarterly dividend of 29.75 cents per share in Q1, marking the ninth consecutive year of dividend increases, demonstrating a long-term commitment to shareholders.
- Market Performance and Valuation: Kinder Morgan's shares have risen 12.9% over the past year compared to an 18.8% increase in composite industry stocks, with an EV/EBITDA of 14.04x, below the industry average of 15.04x, indicating potential investment value.
See More
Quanta Services Appoints Joseph Kim to Board of Directors
- New Board Member: Quanta Services announced the appointment of Joseph Kim to its Board of Directors, whose extensive experience in supply chain and logistics is expected to bring new perspectives and enhance the board's strategic planning capabilities.
- Rich Leadership Experience: Kim currently serves as CEO of Sunoco GP LLC and has held executive roles at notable companies including Pizza Hut and Valero Energy, showcasing his deep background in the energy sector.
- Strategic Planning Expertise: Chairman Doyle N. Beneby noted that Kim's addition will enhance Quanta's capabilities in capital allocation and risk management, driving further growth in the energy infrastructure sector.
- Global Business Expansion: Quanta Services operates across the U.S., Canada, Australia, and other international markets, and Kim's leadership experience will aid the company in safely and efficiently completing various infrastructure projects worldwide.
See More
Sun Pharmaceutical Surpasses Quarterly Profit Estimates Driven by Specialty Drugs
- Quarterly Profit Surge: Sun Pharmaceutical reported a consolidated net profit of 27.14 billion rupees ($283 million) for the quarter ending March 31, marking a 26% increase from 21.50 billion rupees last year, exceeding analysts' expectations of 27.12 billion rupees, indicating strong performance in high-margin drug sectors.
- Specialty Drug Focus: The company's strategic emphasis on high-margin specialty medicines in dermatology, oncology, and obesity has led to this segment accounting for 22.2% of total sales, with revenue rising 20.1% to $354 million, showcasing its ability to counteract declining U.S. sales.
- Overall Revenue Growth: Sun Pharma's total revenue increased nearly 13% to 146.12 billion rupees, surpassing analysts' estimates of 145.26 billion rupees, reflecting the effectiveness of its diversified product portfolio and market strategies.
- Market Performance Insights: Despite a 1.1% decline in U.S. sales, the Indian market saw a robust growth of 14.8%, demonstrating strong domestic demand and positioning the company for enhanced competitiveness in the global market.
See More
Quanta Services Appoints New Board Member
- New Board Member: Quanta Services has appointed Joseph Kim to its Board of Directors, bringing extensive executive experience in supply chain and logistics, which will enhance the company's strategic planning and risk management capabilities.
- Leadership Background: Kim currently serves as CEO of Sunoco GP LLC and has held various executive roles at Pizza Hut and Valero Energy, showcasing his broad influence in the energy sector.
- Board Expectations: Doyle N. Beneby, the independent Chairman of Quanta Services, expressed anticipation for Kim to provide new perspectives to the board, enhancing the company's strategic decision-making and driving business growth.
- Industry Leadership: Quanta Services is a leader in utility and energy infrastructure solutions, and Kim's addition is expected to further solidify the company's market position and enhance its competitiveness in the global arena.
See More
Sunoco LP Shows Strong Technical Setup in Energy Sector
- Technical Breakthrough: Sunoco LP (SUN) stands out in the energy sector with a significant technical breakout above the 2014 peak, indicating a strong long-term bullish trend that is expected to benefit from volatility in crude oil prices.
- Strong Momentum: The monthly MACD shows robust momentum, suggesting that SUN's stock could continue to trend higher over the next few months, with a target price of approximately $78 that appears achievable.
- Relative Outperformance: Relative to the S&P 500 Index, SUN is projected to outperform by 2026, having formed a rounded bottom over the past year that reversed its cyclical downtrend, indicating a strong relative uptrend.
- Solid Support Levels: Former resistance has created strong support around $60, while the 50-day moving average can serve as a trailing stop near $66, ensuring stability for investors amid market fluctuations.
See More
